共 50 条
- [1] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Aapro, Matti S.Rossi, GiorgiaRizzi, GiadaPalmas, MarcoGrunberg, Steven
- [2] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Hesketh, Paul JosephRossi, GiorgiaRizzi, GiadaPalmas, MarcoAlyasova, AnnaDrobner, IgorGralla, Richard J.
- [3] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266Aapro, M.Rossi, G.Rizzi, G.Borroni, M. E.Lorusso, V.Karthaus, M.Grunberg, S.
- [4] A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyANNALS OF ONCOLOGY, 2014, 25 (07) : 1328 - 1333Aapro, M.Rugo, H.Rossi, G.Rizzi, G.Borroni, M. E.Bondarenko, I.Sarosiek, T.Oprean, C.Cardona-Huerta, S.Lorusso, V.Karthaus, M.Schwartzberg, L.Grunberg, S.
- [5] Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Aapro, Matti S.Karthaus, MeinolfSchwartzberg, Lee StevenRossi, GiorgiaRizzi, GiadaBorroni, Maria ElisaPalmas, MarcoRugo, Hope S.
- [6] NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Jordan, KarinRossi, GiorgiaRizzi, GiadaPalmas, MarcoGralla, Richard J.
- [7] Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Zhang, LiLu, ShunFeng, Ji FengDechaphunkul, AruneeChessari, SalvatoreLanzarotti, CorinnaJordan, KarinAapro, Matti S.
- [8] Impact on patients' daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)Aapro, Matti S.Rossi, GiorgiaRizzi, GiadaBorroni, Maria ElisaNagl, Norman G.
- [9] Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomitingFUTURE ONCOLOGY, 2015, 11 (04) : 565 - 577Lorusso, VitoKarthaus, MeinolfAapro, Matti
- [10] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapyANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339Gralla, R. J.Bosnjak, S. M.Hontsa, A.Balser, C.Rizzi, G.Rossi, G.Borroni, M. E.Jordan, K.